Bioventus posts 7% Q1 revenue rise and raises 2026 earnings guidance

Bioventus Inc. (Nasdaq: BVS) has reported first-quarter 2026 net sales of $132.1 million, a 6.6% increase on the $123.9 million recorded in the comparable period a year earlier. The Durham, North Carolina-based company swung to a GAAP net income of $3.1 million from a loss of $2.6 million in Q1 2025, and lifted its full-year adjusted earnings per share and cash-from-operations guidance on the back of what it described as disciplined commercial execution.

Revenue growth was broadly spread. Pain Treatments, the largest segment at $63.4 million, rose 7.7%, though the company noted that roughly $4.2 million of that uplift reflected a one-time rebate benefit tied to a billing process change by a third-party private insurer — a factor investors will discount when assessing the underlying run rate. Surgical Solutions contributed $48.0 million, up 6.2%, driven by US demand for bone-graft substitutes and Ultrasonics. Restorative Therapies, anchored by the EXOGEN bone-stimulation system, added $20.6 million, a 4.6% increase.

Financial highlights

Adjusted EBITDA of $23.9 million advanced 24% year on year, reflecting higher gross profit and favourable foreign-exchange movements. The non-GAAP gross margin widened to 76.4% from 75.3% in Q1 2025. Non-GAAP earnings of $0.15 per diluted Class A share represented an 88% increase from $0.08 a year earlier, driven by improved operating profit and a materially lower interest charge as the company paid down debt.

On 27 March 2026, Bioventus made a discretionary $22.0 million principal prepayment on its term loan, funded by operating cash flows, which reduced long-term debt from approximately $294 million at year-end 2025 to around $272 million. Cash from operations swung to a positive $8.9 million from a $19.3 million outflow in Q1 2025 — a $28.3 million improvement that management attributed to tighter working-capital management.

For full-year 2026, the company raised its adjusted EPS guidance range to $0.75–$0.79 (up $0.02 from prior guidance) and its cash-from-operations outlook to $84–89 million (up $2 million). Net-sales guidance of $600–610 million, implying roughly 6–7% growth, was reaffirmed.

Market context

Bioventus competes in the orthopaedic biologics and bone-healing space alongside larger players such as Stryker, Zimmer Biomet and Smith+Nephew, all of which carry significantly greater scale and diversified device portfolios. The company's narrower focus on active healing — hyaluronic acid viscosupplements, bone-graft substitutes and bone stimulation — leaves it exposed to a specific regulatory risk: the FDA has proposed downclassifying non-invasive bone-growth stimulators, a move that could increase competitive pressure on the EXOGEN franchise, which remains a meaningful contributor to the Restorative Therapies segment.

Internationally, Bioventus is gaining traction, with international net sales rising 17.1% as reported (10.7% in constant currency), led by Surgical Solutions and hyaluronic acid Pain Treatments. The international business, at $15.6 million, remains a small fraction of total revenue, suggesting meaningful headroom if the company can replicate its US commercial model in European and Asian markets. Whether the balance-sheet improvement — and the operating leverage now evident in the non-GAAP figures — is sufficient to attract fresh institutional interest in a stock that has carried a considerable accumulated deficit will depend on the durability of growth in the core Pain Treatments segment once the insurance rebate tailwind normalises.